PDF(Pubmed)
Abstract：
BACKGROUND: Associations of sleep deficiency and methamphetamine use with sexual health and HIV treatment outcomes are poorly understood.
METHODS: A longitudinal cohort of men who have sex with men at risk for or living with HIV (the mSTUDY) was analyzed. This analysis included 1445 study visits among 382 participants. Data were collected from June 2018 to February 2022.
METHODS: Semiannual study visits included self-interviews for sleep deficiency, sexual behaviors, substance use, and HIV treatment. Sleep deficiency was measured using the Pittsburgh Sleep Quality Index. Participants provided specimens for HIV viral load and sexually transmitted infection (STI) testing (chlamydia, gonorrhea, syphilis). Associations between sleep deficiency and STI/HIV outcomes were estimated using multiple logistic regression.
RESULTS: Across visits, the prevalence of sleep deficiency was 56%, with 33% reporting methamphetamine use and 55% living with HIV. Sleep deficiency was associated with reporting at least 1 new anal sex partner (aOR = 1.62, 95% CI: 1.21 to 2.15), exchange sex (aOR = 2.71, 95% CI: 1.15 to 6.39), sex party attendance (aOR = 2.60, 95% CI: 1.68 to 4.04), and missing HIV medications (aOR = 1.91, 95% CI: 1.16 to 3.14). The association between sleep deficiency and exchange sex differed for participants who did and did not report the use of methamphetamine (P = 0.09).
CONCLUSIONS: Sleep deficiency was associated with sexual health and HIV treatment behaviors after accounting for methamphetamine use. Sleep health should be considered in STI/HIV prevention, particularly for those who use methamphetamine.
METHODS: A longitudinal cohort of men who have sex with men at risk for or living with HIV (the mSTUDY) was analyzed. This analysis included 1445 study visits among 382 participants. Data were collected from June 2018 to February 2022.
METHODS: Semiannual study visits included self-interviews for sleep deficiency, sexual behaviors, substance use, and HIV treatment. Sleep deficiency was measured using the Pittsburgh Sleep Quality Index. Participants provided specimens for HIV viral load and sexually transmitted infection (STI) testing (chlamydia, gonorrhea, syphilis). Associations between sleep deficiency and STI/HIV outcomes were estimated using multiple logistic regression.
RESULTS: Across visits, the prevalence of sleep deficiency was 56%, with 33% reporting methamphetamine use and 55% living with HIV. Sleep deficiency was associated with reporting at least 1 new anal sex partner (aOR = 1.62, 95% CI: 1.21 to 2.15), exchange sex (aOR = 2.71, 95% CI: 1.15 to 6.39), sex party attendance (aOR = 2.60, 95% CI: 1.68 to 4.04), and missing HIV medications (aOR = 1.91, 95% CI: 1.16 to 3.14). The association between sleep deficiency and exchange sex differed for participants who did and did not report the use of methamphetamine (P = 0.09).
CONCLUSIONS: Sleep deficiency was associated with sexual health and HIV treatment behaviors after accounting for methamphetamine use. Sleep health should be considered in STI/HIV prevention, particularly for those who use methamphetamine.
摘要：
背景：睡眠不足和使用甲基苯丙胺与性健康和HIV治疗结果的关系知之甚少。
方法：分析了与有HIV风险或感染HIV的男性发生性关系的男性的纵向队列（mStudy）。该分析包括382名参与者中的1445次研究访问。数据收集时间为2018年6月至2022年2月。
方法：半年一次的研究访问包括睡眠不足的自我访谈，性行为,物质使用,艾滋病毒治疗。使用匹兹堡睡眠质量指数测量睡眠不足。参与者提供了用于HIV病毒载量和性传播感染（STI）测试的标本（衣原体，淋病,梅毒）。睡眠不足与STI/HIV结果之间的关联使用多元逻辑回归进行估计。
结果：每次访问，睡眠不足的患病率为56%，33%的人报告使用了甲基苯丙胺，55%的人感染了艾滋病毒。睡眠不足与报告至少1个新的肛门性伴侣相关（aOR=1.62，95％CI：1.21至2.15），交换性(AOR=2.71，95%CI：1.15至6.39)，性派对出勤率(aOR=2.60，95%CI：1.68至4.04)，和缺少HIV药物（aOR=1.91，95％CI：1.16至3.14）。睡眠不足和交换性之间的关系对于那些有和没有报告使用甲基苯丙胺的参与者是不同的（P=0.09）。
结论：考虑使用甲基苯丙胺后，睡眠不足与性健康和HIV治疗行为有关。在性传播感染/艾滋病毒预防中应考虑睡眠健康，特别是那些使用甲基苯丙胺的人。
方法：分析了与有HIV风险或感染HIV的男性发生性关系的男性的纵向队列（mStudy）。该分析包括382名参与者中的1445次研究访问。数据收集时间为2018年6月至2022年2月。
方法：半年一次的研究访问包括睡眠不足的自我访谈，性行为,物质使用,艾滋病毒治疗。使用匹兹堡睡眠质量指数测量睡眠不足。参与者提供了用于HIV病毒载量和性传播感染（STI）测试的标本（衣原体，淋病,梅毒）。睡眠不足与STI/HIV结果之间的关联使用多元逻辑回归进行估计。
结果：每次访问，睡眠不足的患病率为56%，33%的人报告使用了甲基苯丙胺，55%的人感染了艾滋病毒。睡眠不足与报告至少1个新的肛门性伴侣相关（aOR=1.62，95％CI：1.21至2.15），交换性(AOR=2.71，95%CI：1.15至6.39)，性派对出勤率(aOR=2.60，95%CI：1.68至4.04)，和缺少HIV药物（aOR=1.91，95％CI：1.16至3.14）。睡眠不足和交换性之间的关系对于那些有和没有报告使用甲基苯丙胺的参与者是不同的（P=0.09）。
结论：考虑使用甲基苯丙胺后，睡眠不足与性健康和HIV治疗行为有关。在性传播感染/艾滋病毒预防中应考虑睡眠健康，特别是那些使用甲基苯丙胺的人。
